The investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in clinical trials compared to Sanofi’s Aubagio as Novartis aims to refresh the Swiss drugmaker’ portfolio of medicines in neurological diseases.

Since 2009, May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.